ライフサイエンスコーパス: amphotericin B

1 itial treatment or as step-down therapy from amphotericin B.

2 oxic effects at the maximal concentration of amphotericin B.

3 tant to the antifungal drugs fluconazole and amphotericin B.

4 zole was the most affected drugs followed by amphotericin B.

5 eceive voriconazole, and 10 were switched to amphotericin B.

6 ique in its ability to develop resistance to amphotericin B.

7 i that is inherently resistant to azoles and amphotericin B.

8 on antifungals were less cost-effective than amphotericin B.

9 d to the ion channel-forming natural product amphotericin B.

10 ients (53%) were also treated with liposomal amphotericin B.

11 the ion channel and antifungal activities of amphotericin B.

12 reased susceptibility to the antifungal drug amphotericin B.

13 id chromatography-MS-MS were used to measure amphotericin B.

14 ure the antifungal effect of macrophages and amphotericin B.

15 ients before and 3-4 wk after treatment with Amphotericin B.

16 ith an efficacy similar to that of liposomal amphotericin B.

17 e fungal burden when combined with liposomal amphotericin B.

18 of the antifungal effect of macrophages and amphotericin B.

19 ical debridement, in addition to intravenous amphotericin B.

20 zoles was delayed in comparison to that with amphotericin B.

21 a combination of 5-fluorocytosine (5FC) and amphotericin B.

22 d antifungals: fluconazole, caspofungin, and amphotericin B.

23 anomolar antifungal activity in synergy with amphotericin B.

24 f >28 and 2 times higher potency compared to amphotericin B.

25 ess cytotoxicity to healthy macrophages than amphotericin B.

26 gainst mucormycosis with efficacy similar to amphotericin B.

27 y against the strains tested was shown to be amphotericin B.

28 ) topical natamycin 5% plus CXL, (3) topical amphotericin B 0.15% alone, and (4) topical amphotericin

29 mug/ml), isavuconazole (4 and 4 mug/ml), and amphotericin B (0.25 and 0.5 mug/ml).

30 Participants received amphotericin B (0.7 to 1.0 mg per kilogram of body weigh

31 andard therapy with 7-14 days of intravenous amphotericin B (0.7-1.0 mg/kg per day) and oral fluconaz

32 Control limits (amphotericin B, 1 to 4 microg/ml; itraconazole, 0.06 to

33 mycetes), BBL caspofungin 5-microg disk, and amphotericin B 10-microg (zygomycetes only).

34 voriconazole (10 mg/kg p.o. BID), liposomal amphotericin B (10 mg/kg intraperitoneally [i.p.] once a

35 were as follows: P. variotii ATCC MYA-3630, amphotericin B (15 to 24 mm), itraconazole (20 to 31 mm)

36 e (33 to 43 mm); A. fumigatus ATCC MYA-3626, amphotericin B (18 to 25 mm), itraconazole (11 to 21 mm)

37 d voriconazole (25 to 33 mm); and C. krusei, amphotericin B (18 to 27 mm), itraconazole (18 to 26 mm)

38 er applying topical natamycin (5 %), topical amphotericin B (1mg/ml), topical fluconazole (2mg/ml) an

39 minimum inhibitory concetrations (MICs) for amphotericin B (2.6 +/- 3.5 mug/mL), fluconazole (36.9 +

40 iaceus died despite treatment with liposomal amphotericin B, 3 mg/kg/d, and a young girl with pemphig

41 with IV caspofungin (50 mg/d) and liposomal amphotericin B (300 mg/d).

42 oodstream infection isolates of C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates

43 patient was treated initially with liposomal amphotericin B, 430 mg daily, but changed to voriconazol

44 ungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

45 zole and elevated MIC to voriconazole (81%), amphotericin B (61%), flucytosine (5FC) (3%), and echino

46 as observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respectively; flucytosine

47 (P), flucytosine (FC), caspofungin (C), and amphotericin B (A) were tested with 212 Candida isolates

48 Here we report that apical addition of amphotericin B, a small molecule that forms unselective

49 Here, we describe that amphotericin B activates these cells through engaging My

50 ailable in Africa and most of Asia, and safe amphotericin B administration requires patient hospitali

51 upplemented with different concentrations of amphotericin B after inoculation with Candida albicans i

52 tic action in combination with cisplatin and amphotericin B against cancer and fungal cells, respecti

53 ainst T. cruzi and slightly more potent than amphotericin B against L. amazonensis.

54 We conclude that RIT is more effective than amphotericin B against systemic infection with C. neofor

55 B and flucytosine than among those receiving amphotericin B alone (15 vs. 25 deaths by day 14; hazard

56 tericin B plus flucytosine, as compared with amphotericin B alone, is associated with improved surviv

57 shown to reduce mortality, as compared with amphotericin B alone.

58 Amphotericin B also restored airway surface liquid pH, v

59 luation of two novel PEG amide conjugates of amphotericin B (AMB (1)): AB1 (4) and AM2 (5).

60 p<0.001), and more likely to be treated with amphotericin B (AmB) (87% vs 24%, p<0.001) and flucytosi

61 amestolkiae The potent in vitro activity of amphotericin B (AMB) and terbinafine (TRB) and of the ec

62 gillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therap

63 of 10 patients with lung infection received amphotericin B (AMB) induction therapy (6 with 5-flucyto

64 Amphotericin B (AmB) is a clinically vital antimycotic b

65 Amphotericin B (AmB) is a prototypical small molecule na

66 Amphotericin B (AmB) is an effective but toxic antifunga

67 Amphotericin B (AmB) is the archetype for small molecule

68 Amphotericin B (AmB) is the standard antifungal drug use

69 Amphotericin B (AMB) is used to treat both fungal and le

70 demonstrated that, compared with 2 weeks of amphotericin B (AmB) plus flucystosine (5FC), 1 week of

71 Current standard initial therapy consists of amphotericin B (AmB) plus flucytosine (5-FC), but 5-FC r

72 stance to the ergosterol-targeting fungicide amphotericin B (AmB) revealed that the two growth modes

73 e genetically distinct and more resistant to amphotericin B (AmB) than the isolates from central Colo

74 ine A (CSA) to enhance the activity of PHMB, amphotericin B (AMB), and voriconazole (VCZ) against Asp

75 We determined species-specific ECVs for amphotericin B (AMB), flucytosine (FC) and itraconazole

76 Amphotericin B (AmB), is a highly effective antileishman

77 tute (CLSI) M38-A2 broth dilution method for amphotericin B (AMB), itraconazole (ITR), voriconazole (

78 relies exclusively on chemotherapy including amphotericin B (AmB), miltefosine (hexadecylphosphocholi

79 e third major antifungal used in the clinic, amphotericin B (AmB), remains extremely rare despite 50

80 Amphotericin B (AmB), the most effective drug against le

81 Susceptibility against amphotericin B (AmB), voriconazole (VCZ), and natamycin

82 hat has the ability to develop resistance to amphotericin B (AmB).

83 h 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6 equal dose infusi

84 This polymer is slightly less effective than amphotericin B (AmpB) for two strains, but the polymer i

85 For amphotericin B, an MIC of </=0.5 mug/ml was significantl

86 e surgical and antifungal therapy (liposomal amphotericin B and a broad-spectrum triazole pending myc

87 rd, systemic injections of nontoxic doses of amphotericin B and another activator, macrophage colony-

88 the ergosterol molecule-targeting antifungal amphotericin B and antagonizes that of the ergosterol pa

89 probes for determination of MICs (FMICs) of amphotericin B and caspofungin against Candida spp. and

90 hin one well dilution, with the MICs against amphotericin B and caspofungin for all species.

91 Amphotericin B and caspofungin had minimal circuit clear

92 All isolates tested were susceptible to amphotericin B and caspofungin, but 11% were resistant o

93 and had reduced in vitro susceptibilities to amphotericin B and caspofungin, which correlated with cl

94 -mediated direct binding interaction between amphotericin B and ergosterol is required for both formi

95 omoting a direct binding interaction between amphotericin B and ergosterol.

96 ns and Cryptococcus neoformans comparable to amphotericin B and fluconazole.

97 ong with combination antifungal therapy with amphotericin B and fluconazole.

98 dely accepted treatment guidelines recommend amphotericin B and flucytosine as first-line induction t

99 d by days 14 and 70 among patients receiving amphotericin B and flucytosine than among those receivin

100 to 24, 48, and 72 h), and (iii) seven disks (amphotericin B and itraconazole 10-microg disks, voricon

101 trategy and the use of lipid formulations of amphotericin B and major surgery when feasible as the mo

102 potentiates the activity of the antifungals amphotericin B and micafungin.

103 Liposomal amphotericin B and MIL combination for treating PKDL is

104 He was treated with liposomal amphotericin B and multiple debridements, with no diseas

105 nazole that was similar to that reported for amphotericin B and posaconazole.

106 cormycosis to guide the timely initiation of amphotericin B and possible surgical intervention, a coo

107 tro and in vivo antagonism between liposomal amphotericin B and ravuconazole in simultaneous treatmen

108 for mortality, whereas lipid formulations of amphotericin B and surgery improved outcomes.

109 the azoles but also the salvage therapeutics amphotericin B and terbinafine without significantly aff

110 Whether the interaction between amphotericin B and triazoles is antagonistic against inv

111 EAs for amphotericin B and voriconazole were >90% for most poten

112 ic gramicidin and the known antifungal agent amphotericin B and were not toxic at their antifungal MI

113 ant strains of E.coli, as well as effects of amphotericin-B and miconazole on S. cerevisiae through t

114 nts (voriconazole, with or without liposomal amphotericin B), and 24 required surgical debridement.

115 olates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resist

116 e, voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin for 383 invasive Candida

117 he activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely through increasi

118 l drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more wi

119 om all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin.

120 Voriconazole, posaconazole, itraconazole, amphotericin B, and micafungin had the most potent in vi

121 in combination with antibiotics (vancomycin, amphotericin B, and nalidixic acid), and the efficacy of

122 manials (antimony, miltefosine, paromomycin, amphotericin B, and pentamidine).

123 of fluconazole, voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin, and micafung

124 erior efficacy compared with older azoles or amphotericin B as first-line or empiric therapy for fung

125 , voriconazole, was superior to conventional amphotericin B as primary therapy for invasive aspergill

126 0x minimum inhibitory concentration (MIC) or amphotericin B at 0.25x, 0.5x, 1x, or 10x MIC.

127 trols, with the exception of Optisol-GS plus amphotericin B at 10x MIC, donor corneas in supplemented

128 All patients received amphotericin B at a dose of 1 mg per kilogram of body we

129 rneas stored in Optisol-GS supplemented with amphotericin B at any concentration compared with paired

130 Two vials each were supplemented with amphotericin B at concentrations of 0.06, 0.12, or 0.225

131 Combinations of 12f with fluconazole and amphotericin B at subinhibitory concentration were syner

132 m 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for da

133 rvival rates and potentiated the activity of amphotericin B. bFGF-containing regimens were associated

134 ically important antifungals nystatin A1 and amphotericin B, but it has several distinctive structura

135 The patient initially received liposomal amphotericin B, but the infection continued to progress,

136 traconazole, posaconazole, voriconazole, and amphotericin B by CLSI methods.

137 0.076) and Etest (1.00, SE = 0.218) and for amphotericin B by disk diffusion (1.00, SE = 0.098).

138 crobials (meropenem, piperacillin, liposomal amphotericin B, caspofungin, and voriconazole).

139 Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole,

140 usceptibility of 183 filamentous isolates to amphotericin B, caspofungin, itraconazole, posaconazole,

141 The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazol

142 ectrum-beta-lactamase (ESBL) and vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plat

143 ssion, lipid biosynthesis, susceptibility to amphotericin B, cellular metabolism, and protein phospho

144 l Na(+), K(+)-ATPase, indicating that apical amphotericin B channels functionally interfaced with thi

145 nazole (FLC), micafungin, 5- flucytosine and amphotericin B compared to younger (0-3 generation) cell

146 ortality rate, whereas lipid formulations of amphotericin B compared with amphotericin B deoxycholate

147 days in lung transplant recipients achieved amphotericin B concentrations in ELF above minimum inhib

148 ition; 4 corneas each received the different amphotericin B concentrations.

149 is meta-analysis of 13 studies revealed that amphotericin B delivered as a locally prepared lipid emu

150 we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (

151 Since the late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully

152 py or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients

153 photericin B (LAmB) compared to conventional amphotericin B deoxycholate (DAmB) is due to several fac

154 formulations of amphotericin B compared with amphotericin B deoxycholate (OR 0.09, 95% CI 0.02-0.50,

155 Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the reco

156 R) of 3 cryptococcal induction regimens: (1) amphotericin B deoxycholate for 4 weeks; (2) amphoterici

157 Amphotericin B deoxycholate is recommended against, beca

158 lly allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment whi

159 wenty-four of 34 patients (71%) treated with amphotericin B deoxycholate, 4/12 (33%) treated with a t

160 Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substanti

161 s on three old, off-patent antifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazol

162 rming units from the lung and brain, whereas amphotericin B did not decrease the number of colony-for

163 zone diameters (-0.42) precludes the use of amphotericin B disk diffusion for susceptibility testing

164 Treatment with ergosterol-specific amphotericin B does not.

165 induced amastigote death at doses similar to amphotericin B doses, while exhibiting much less cytotox

166 All patients received inhaled amphotericin B during their initial LT hospitalization,

167 that SensiQuattro performed best in testing amphotericin B (EA, 100%), voriconazole (EA, 93.7%), and

168 emented with a 0.255-mug/mL concentration of amphotericin B effectively eliminated fungal contaminant

169 th concentrations of 0.06 and 0.12 mug/mL of amphotericin B eliminated all fungal contaminants by day

170 ented with the 0.255-mug/mL concentration of amphotericin B eliminated all fungal contaminants by day

171 e diseases have been published and recommend amphotericin B, fluconazole, or caspofungin as the prima

172 C. krusei) against seven antifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole,

173 ns, and 426 isolates of Candida spp. against amphotericin B, flucytosine, and voriconazole.

174 ailable for older antifungal agents, such as amphotericin B, flucytosine, or itraconazole.

175 st MICs (94 to 97%) and by both methods with amphotericin B for all species (95 to 99.3%).

176 nospecies biofilms reduced susceptibility to amphotericin B for C. tropicalis and C. glabrata.

177 Antifungal supplementation with amphotericin B for EK grafts was the most cost-effective

178 mbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole

179 ring an echinocandin with either an azole or amphotericin B formulation as therapy for invasive asper

180 .4%) patients were initially treated with an amphotericin B formulation for a median duration of 2 we

181 The enhanced understanding of amphotericin B function derived from these synthesis-ena

182 sine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days.

183 pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177

184 We have evaluated liposomal amphotericin B in 20 patients with DL in an open clinica

185 % and antifungals in 87% of cases (liposomal amphotericin B in 61%).

186 mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.

187 Concentrations of amphotericin B in ELF (median, 25-75 IQR) were at 4 hr (

188 ffusion methods for testing posaconazole and amphotericin B in the clinical laboratory against the sp

189 ospectively determined the concentrations of amphotericin B in the epithelial lining fluid (ELF) and

190 Administration of polymyxin/tobramycin/amphotericin B in the oropharynx and the gastric tube pl

191 sential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of t

192 eved with intravenous phospholipid-complexed amphotericin B initially, followed by long-term combinat

193 ceptibility to oral fluconazole, intravenous amphotericin B, intravitreal amphotericin B, oral vorico

194 cans cells were resistant to fluconazole and amphotericin B, irrespective of the medium used to form

195 mphogel, a dextran-based hydrogel into which amphotericin B is adsorbed.

196 usly reported that the antifungal medication amphotericin B is an activator of circulating monocytes,

197 Liposomal amphotericin B is an effective therapy for DL, with a hi

198 irst-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenou

199 Amphotericin B is the archetype for small molecules that

200 sceptibility data for Chrysosporium zonatum, amphotericin B is the most active drug, itraconazole sus

201 vious severe infusion reactions to liposomal amphotericin B is unclear.

202 The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole

203 t our isolates appeared to be susceptible to amphotericin B, itraconazole, voriconazole, ravuconazole

204 (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningi

205 orting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconazole, micafungin and pla

206 The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination with flucy

207 icacy of combination therapy using liposomal amphotericin B (LAmB) and MIL for treating PKDL.

208 profile and antifungal efficacy of liposomal amphotericin B (LAmB) compared to conventional amphoteri

209 nce its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent

210 ity of high-dose weekly (10 mg/kg) liposomal amphotericin B (LamB) for antifungal prophylaxis in live

211 ed-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse model and ana

212 y of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was assessed in a se

213 We evaluated once weekly intravenous amphotericin B lipid complex (ABLC), given its broad-spe

214 a tertiary care cancer center and found that amphotericin B lipid complex administration was uneventf

215 r aerosolized nebulization (AeroEclipse), of amphotericin B lipid complex at 1 mg/kg every 24 hr for

216 spite receiving prophylaxis with aerosolized amphotericin B lipid complex during the transplant hospi

217 ifungal prophylaxis consisted of aerosolized amphotericin B lipid complex during the transplant hospi

218 stration through aerosolized nebulization of amphotericin B lipid complex every 24 hr for 4 days in l

219 ist regarding the pharmacokinetic profile of amphotericin B lipid complex in lung transplant recipien

220 The tolerability of amphotericin B lipid complex in patients with previous s

221 Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosin

222 esistance to amphotericin B, we conducted an amphotericin B loss-of-function screen in Chinese hamste

223 sistance to the cholesterol-binding compound amphotericin B methyl ester (AME) by acquiring mutations

224 sm by which the cholesterol-binding compound amphotericin B methyl ester (AME) inhibits human immunod

225 eported that a cholesterol-binding compound, amphotericin B methyl ester (AME), blocks HIV-1 entry an

226 compound, the polyene antifungal antibiotic amphotericin B methyl ester (AME).

227 Decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibi

228 o identify two of the six isolates with high amphotericin B MICs.

229 nd carboxylic acid appendages on neighboring amphotericin B molecules are not required for ion channe

230 lures of micafungin (n = 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively.

231 er the antimicrobial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azloci

232 All isolates had MICs at 48 h of amphotericin B of > or = 1 microg/ml and of echinocandin

233 rlo simulations showed that human dosages of amphotericin B of at least 0.6 mg/kg were required to ac

234 uced the minimal inhibitory concentration of amphotericin B or fluconazole when used in combination w

235 inocandin antifungals but not by exposure to amphotericin B or flucytosine.

236 ecific circumstances, including testing with amphotericin B or triazoles for non-Aspergillus molds (M

237 tration of an azole (OR, 0.06; P < 0.001) or amphotericin B (OR, 0.35; P = 0.05) was protective.

238 nventional therapy consisting of a triazole, amphotericin B, or a combination of both.

239 after infection with (213)Bi-18B7 antibody, amphotericin B, or both.

240 exposure of Rhizopus oryzae to itraconazole, amphotericin B, or caspofungin and exposure of Aspergill

241 ecific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant.

242 le, intravenous amphotericin B, intravitreal amphotericin B, oral voriconazole, and intravitreal vori

243 tration showing absence of visual growth) of amphotericin B, overall agreement levels were 90 to 93%

244 Treatment with amphotericin B, particularly in combination with MCSF, i

245 Using simultaneous fura-2 Ca(2+) imaging and amphotericin B perforated patch-clamp electrophysiology,

246 Voltage-clamp experiments using amphotericin B-permeablized monolayers revealed that the

247 A survival benefit of amphotericin B plus fluconazole was not found.

248 The US guidelines recommend treatment with amphotericin B plus flucytosine for at least 2 weeks, fo

249 In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mo

250 Amphotericin B plus flucytosine was associated with sign

251 One-week amphotericin B plus flucytosine was associated with the

252 ryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative the

253 Amphotericin B plus flucytosine, as compared with amphot

254 nts, the use of topical polymyxin/tobramycin/amphotericin B plus mupirocin/chlorhexidine was associat

255 Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subse

256 presented three important hydrogen bonds and amphotericin B presented two hydrogen bonds that stabili

257 hich counteracts virus inhibition by IFITM3, Amphotericin B, prevented the IFITM3-mediated rigidifica

258 r perspectives for the use of 2 antifungals, amphotericin B products and posaconazole, with activity

259 The exception was amphotericin B (R values of 0.68 and 0.5 for disk and ta

260 ited potent antibiofilm activity, similar to amphotericin B, reducing the metabolic activity of adher

261 Inhaled formulations of amphotericin B remain the most widely studied option for

262 ong antifungal activity against wildtype and amphotericin B-resistant strains of Candida albicans at

263 avuconazole, voriconazole, itraconazole, and amphotericin B, respectively.

264 rturbation studies with the IFITM antagonist amphotericin B revealed that modulation of membrane prop

265 In addition, the antifungal amphotericin B reversed Serinc restriction, presumably b

266 These results do not prove that amphotericin B should be added to Optisol-GS; larger-sca

267 pofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.

268 Comparison with clinically used amphotericin B shows similar antifungal behaviour withou

269 l inhibitory concentration of 2 mg/L against amphotericin B, suggesting resistance to the drug.

270 dy, 12 pairs of corneas were divided between amphotericin B supplementation and the control condition

271 case, a corneal endothelial graft stored in amphotericin B-supplemented CSM was the most cost-effect

272 light-exposed compared with light-protected amphotericin B-supplemented Optisol-GS was identified.

273 t, there was no growth of either organism in amphotericin B-supplemented vials, except at 0.25x and 0

274 agreement of fluconazole, voriconazole, and amphotericin B susceptibility results by disk diffusion.

275 d isolates except zygomycetes, and 10-microg amphotericin B tablets against zygomycete isolates only.

276 For amphotericin B, the best correlation between reference M

277 i.Despite relapsing 6 weeks after completing amphotericin B therapy, the patient made a complete reco

278 ctively screened twice a week, and liposomal amphotericin-B therapy initiated based on a positive qPC

279 Each drug poses unique access challenges: amphotericin B through cost, toxic effects, and insuffic

280 y fungal infection, however, the addition of amphotericin B to Optisol-GS deserves further investigat

281 The addition of amphotericin B to Optisol-GS may significantly improve a

282 p=0.98), most of which were associated with amphotericin B toxicity.

283 conazole cases was similar to 13 (39%) of 33 amphotericin B-treated matched controls (weighted all-ca

284 ART-naive adults aged>/=21 years initiating amphotericin B treatment for CM were randomized to ART i

285 therapy was additive with that of liposomal amphotericin B treatment.

286 active at the time of the IFI, and any prior amphotericin B use; among SOT recipients, fluconazole no

287 The species has a higher amphotericin B, voriconazole, and itraconazole MIC and c

288 asty (EK) and penetrating keratoplasty (PK); amphotericin B, voriconazole, caspofungin, and combinati

289 r minimal effective concentrations (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin,

290 The success rate with liposomal amphotericin B was 4-fold higher even when controlling f

291 Treatment with bFGF plus amphotericin B was associated with neutrophil influx int

292 Although liposomal amphotericin B was considered well tolerated, mild adver

293 The MIC for amphotericin B was defined as the lowest concentration o

294 formed mixed- Candida species biofilms while amphotericin B was potent.

295 Liposomal amphotericin B was started within a median of 1 (interqu

296 cterize prevention of posttreatment relapse, amphotericin B was used to kill approximately 90-95% of

297 an be isolated on the basis of resistance to amphotericin B, we conducted an amphotericin B loss-of-f

298 To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously wit

299 d to improve the tolerability of intravenous amphotericin B, while optimizing its clinical efficacy.

300 al antifungal therapy, including intrathecal amphotericin B, while results of fungal cultures were pe